June 28 (UPI) -- The U.S. Food and Drug Administration has taken two new steps to provide more lower-cost prescription drug alternatives and increase competition.
As part of the FDA's Drug Competition Action Plan rolled out in May, the agency on Tuesday published a list of off-patent, off-exclusivity branded drugs without approved generics and implemented a new policy to expedite the review of generic drug applications in places where competition is limited.